Blog

The Evolving Role of Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer – International Society of Liquid Biopsy

International Society of Liquid Biopsy/X

Feb 11, 2025, 08:06

The Evolving Role of Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer – International Society of Liquid Biopsy

International Society of Liquid Biopsy shared a post on X:

“ISLB-Endorsed Seminar: The Evolving Role of Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer.

Expert Insights from:

Prof. Frédérique Penault-Llorca (Pathologist, Univ. of Clermont-Ferrand, France).
Dr. Aditya Bardia (Medical Oncologist, UCLA, USA).

Key Takeaways:

Liquid biopsy complements tumor biopsy for molecular profiling.
Detects critical mutations (ESR1, PIK3CA) linked to therapy resistance.
NGS testing follows ESMO & NCCN guidelines for precision medicine.
Endorsed by ISLB, this seminar highlights the latest advances in biomarker testing & patient management!

Watch now.”

Aditya Bardia cancer ESMO fight against cancer Frédérique Penault-Llorca Global fight against cancer International Society of Liquid Biopsy ISLB liquid biopsy MBC metastatic breast cancer NCCN OncoDaily Oncology UCLA University of Clermont-Ferrand

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to OncoDaily on Pediatric Oncology Funding